EPHA3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04629(EPHA3 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04629(EPHA3 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The EPHA3 antibody targets the Ephrin type-A receptor 3 (EPHA3), a member of the Eph receptor tyrosine kinase family involved in cell-cell communication, tissue development, and disease processes. EPHA3 binds membrane-anchored ephrin ligands, triggering bidirectional signaling pathways that regulate cell adhesion, migration, and differentiation. Initially studied for its role in nervous system development, EPHA3 has gained attention in oncology due to its aberrant expression in cancers like leukemia, lung cancer, and glioblastoma. Overexpression or mutations in EPHA3 are linked to tumor progression, metastasis, and therapy resistance, making it a potential therapeutic target.

EPHA3 antibodies, including monoclonal and polyclonal variants, are used to study receptor localization, expression levels, and signaling mechanisms. Therapeutic antibodies blocking EPHA3 activity have shown preclinical efficacy in inhibiting tumor growth and sensitizing cancer cells to chemotherapy. However, challenges remain, such as understanding context-dependent roles (e.g., tumor-suppressive vs. oncogenic effects) and minimizing off-target effects. Research continues to explore EPHA3's dual functions in cancer and its potential as a biomarker or immunotherapy target, highlighting its complex yet promising role in precision medicine.